<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654131</url>
  </required_header>
  <id_info>
    <org_study_id>H-18000085</org_study_id>
    <nct_id>NCT03654131</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy vs. Microwave Ablation for Colorectal Cancer Patients With Metastatic Disease in the Liver</brief_title>
  <official_title>Stereotactic Body Radiation Therapy vs. Microwave Ablation for Colorectal Cancer Patients With Metastatic Disease in the Liver - a Randomized Phase II Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized phase II trial between microwave ablation (MWA) and stereotactic
      body radiotherapy (SBRT) - two standard treatment modalities for colorectal patients with
      metastatic disease in the liver. Primary endpoint is freedom form local lesion progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer patients with 1-3 liver metastases (diameter ≤4.0 cm) found unsuitable for
      resection are randomized 1:1 to either MWA or SBRT. Chemotherapy is allowed. Curative
      treatment of extrahepatic disease must be initiated in patients with lung metastases and/or
      primary tumors. Patients will be analyzed according to the intention-to-treat principle.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Anticipated">July 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from local lesion progression (analyzed on patient-level)</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as the time from randomization to local progression
Censoring: death from any cause, last follow-up
No censoring on disease progression outside of the treated lesions
Local lesion progression is defined as &gt;20% increase in the longest diameter and minimum 5 mm increase talking as reference the smallest longest diameter recorded since the treatment started in any of the treated lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as the time from randomization to death from any cause
Censoring: last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from local lesion progression (analyzed on lesion-level)</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as the time from randomization to local progression
Censoring: death from any cause, last follow-up
No censoring on disease progression outside of the treated lesions
Local lesion progression is defined as &gt;20% increase in the longest diameter and minimum 5 mm increase talking as reference the smallest longest diameter recorded since the treatment started in any of the treated lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>≥ grade 3 toxicity potentially associated with the treatment</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as the time from randomization to first ≥ grade 3 toxicity using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Censoring: death from any cause, last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile as descriptive statistics</measure>
    <time_frame>3 years</time_frame>
    <description>Using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as descriptive statistics: EORTC QLQ-C30</measure>
    <time_frame>3 years</time_frame>
    <description>Using EORTC QLQ-C30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Carcinoma</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>MWA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous ultrasound-guided MWA or open surgery MWA. The patient is fully anesthetized during the treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 fractions of 15 Gy (in total 45 Gy), 3 fractions per week. The dose is prescribed to the PTV encompassing 67% isodose. The SBRT plan is normalized such that the mean dose to the GTV is 100% = 67.5 Gy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MWA</intervention_name>
    <description>Patients are allocated to one of the two arms in a 1:1 randomization</description>
    <arm_group_label>MWA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Patients are allocated to one of the two arms in a 1:1 randomization</description>
    <arm_group_label>SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Colorectal cancer patients with oligo metastatic disease in the liver (1 to 3 tumors),
             and where metastases are found unsuitable for resection because of

               1. non-resectability

               2. small metastasis localized deep in the liver, where a parenchyma sparing
                  intervention is preferred over an extensive resection

               3. previous extensive liver surgery

               4. comorbidity

          2. The multidisciplinary team should all agree that both percutaneous or open surgical
             MW-ablation and SBRT are safe as first treatment choice for the individual patient.

          3. Tumor sizes ≤4.0 cm

          4. Age &gt; 18 years

          5. Signed informed consent

        Exclusion Criteria:

          1. Previous radiotherapy to the liver

          2. Liver volume &lt; 700 ml

          3. Another active cancer disease within the past 36 months

          4. Not able to understand written or oral protocol information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Righospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Signe Normann Risum, MD, PhD</last_name>
      <phone>+45 35453545</phone>
      <email>rigshospital.rigshospitalet@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Signe Normann Risum, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Signe Normann Risum</investigator_full_name>
    <investigator_title>Senior consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03654131/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03654131/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

